Tech Transfer eNews Blog
Industry-Sponsored Research Management sample issue

UChicago raises $750,000 for its migraine-fighting nasal spray

By Jesse Schwartz
Published: April 4th, 2018

A University of Chicago (UChicago) spinout has raised $750,000 to commercialize a nasal spray that treats migraines.

Seurat Therapeutics will use the funds to begin clinical testing of its product, a nasal-delivered drug that has been shown to stop the underlying cause of migraines in rat studies by reducing the hyperactivity of neurons in the brain.

“We’re working on a simple solution to a very complex problem,” says Richard Kraig, chief scientific officer at Seurat Therapeutics. “We think this treatment can prevent migraines in the millions of frequent and chronic migraine sufferers, and be the first treatment to address the underlying causes of migraines rather than just the symptoms of severe pain and life-altering disability.”

Investors in the seed round include both start-up team members and outside investors such as UChicago’s Polsky Innovation Fund. This spring, Seurat will compete in the Polsky Center’s New Venture Challenge, one of the top university start-up accelerator programs in the country.

Source: ChicagoInno

Posted under: Tech Transfer e-News

Twitter Facebook Linkedin Pinterest Email

No Comments so far ↓

There are no comments yet...Kick things off by filling out the form below.

Leave a Comment